schliessen

Filtern

 

Bibliotheken

Bioreducible heparin-based nanogel drug delivery system

Bioreducible heparin (HEP)-based nanogels were prepared by derivatizing HEP with vinyl group followed by copolymerizing with cystamine bisacrylamide in aqueous medium in the absence of surfactant. The hydrodynamic diameter of the HEP nanogels could be tuned in the range from 80 to 200 nm. Doxorubici... Full description

Journal Title: Biomaterials January 2015, Vol.39, pp.260-268
Main Author: Wu, Wei
Other Authors: Yao, Wei , Wang, Xin , Xie, Chen , Zhang, Jialiang , Jiang, Xiqun
Format: Electronic Article Electronic Article
Language: English
Subjects:
ID: ISSN: 0142-9612 ; DOI: 10.1016/j.biomaterials.2014.11.005
Link: http://dx.doi.org/10.1016/j.biomaterials.2014.11.005
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: sciversesciencedirect_elsevierS0142-9612(14)01161-2
title: Bioreducible heparin-based nanogel drug delivery system
format: Article
creator:
  • Wu, Wei
  • Yao, Wei
  • Wang, Xin
  • Xie, Chen
  • Zhang, Jialiang
  • Jiang, Xiqun
subjects:
  • Heparin
  • Nanogel
  • Doxorubicin
  • Antitumor
ispartof: Biomaterials, January 2015, Vol.39, pp.260-268
description: Bioreducible heparin (HEP)-based nanogels were prepared by derivatizing HEP with vinyl group followed by copolymerizing with cystamine bisacrylamide in aqueous medium in the absence of surfactant. The hydrodynamic diameter of the HEP nanogels could be tuned in the range from 80 to 200 nm. Doxorubicin (DOX) was loaded into the HEP nanogels, and high drug loading content (30%) and efficiency (90%) were achieved. In vitro drug release test revealed that this drug delivery system exhibited strongly redox-sensitive drug release behavior that would greatly favor the in vivo drug delivery performance of the nanogels. After injected into tumor-bearing mice through tail vein, the DOX-loaded HEP nanogels showed remarkable accumulation in tumors as demonstrated by in vivo near infared fluorescence imaging and ex vivo DOX concentration measurements. The doxorubicin accumulation at tumor site goes beyond 9% injected dose per gram of tumor through such delivery system, making that DOX-loaded HEP nanogels have significantly superior in vivo antitumor activity.
language: eng
source:
identifier: ISSN: 0142-9612 ; DOI: 10.1016/j.biomaterials.2014.11.005
fulltext: fulltext
issn:
  • 01429612
  • 0142-9612
url: Link


@attributes
ID809604932
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordidS0142-9612(14)01161-2
sourceidsciversesciencedirect_elsevier
recordidTN_sciversesciencedirect_elsevierS0142-9612(14)01161-2
sourcesystemOther
pqid1660092570
display
typearticle
titleBioreducible heparin-based nanogel drug delivery system
creatorWu, Wei ; Yao, Wei ; Wang, Xin ; Xie, Chen ; Zhang, Jialiang ; Jiang, Xiqun
ispartofBiomaterials, January 2015, Vol.39, pp.260-268
identifierISSN: 0142-9612 ; DOI: 10.1016/j.biomaterials.2014.11.005
subjectHeparin ; Nanogel ; Doxorubicin ; Antitumor
descriptionBioreducible heparin (HEP)-based nanogels were prepared by derivatizing HEP with vinyl group followed by copolymerizing with cystamine bisacrylamide in aqueous medium in the absence of surfactant. The hydrodynamic diameter of the HEP nanogels could be tuned in the range from 80 to 200 nm. Doxorubicin (DOX) was loaded into the HEP nanogels, and high drug loading content (30%) and efficiency (90%) were achieved. In vitro drug release test revealed that this drug delivery system exhibited strongly redox-sensitive drug release behavior that would greatly favor the in vivo drug delivery performance of the nanogels. After injected into tumor-bearing mice through tail vein, the DOX-loaded HEP nanogels showed remarkable accumulation in tumors as demonstrated by in vivo near infared fluorescence imaging and ex vivo DOX concentration measurements. The doxorubicin accumulation at tumor site goes beyond 9% injected dose per gram of tumor through such delivery system, making that DOX-loaded HEP nanogels have significantly superior in vivo antitumor activity.
languageeng
source
version6
lds50peer_reviewed
links
openurl$$Topenurl_article
backlink$$Uhttp://dx.doi.org/10.1016/j.biomaterials.2014.11.005$$EView_record_in_ScienceDirect
openurlfulltext$$Topenurlfull_article
search
creatorcontrib
0Wu, Wei
1Yao, Wei
2Wang, Xin
3Xie, Chen
4Zhang, Jialiang
5Jiang, Xiqun
titleBioreducible heparin-based nanogel drug delivery system
descriptionBioreducible heparin (HEP)-based nanogels were prepared by derivatizing HEP with vinyl group followed by copolymerizing with cystamine bisacrylamide in aqueous medium in the absence of surfactant. The hydrodynamic diameter of the HEP nanogels could be tuned in the range from 80 to 200 nm. Doxorubicin (DOX) was loaded into the HEP nanogels, and high drug loading content (30%) and efficiency (90%) were achieved. In vitro drug release test revealed that this drug delivery system exhibited strongly redox-sensitive drug release behavior that would greatly favor the in vivo drug delivery performance of the nanogels. After injected into tumor-bearing mice through tail vein, the DOX-loaded HEP nanogels showed remarkable accumulation in tumors as demonstrated by in vivo near infared fluorescence imaging and ex vivo DOX concentration measurements. The doxorubicin accumulation at tumor site goes beyond 9% injected dose per gram of tumor through such delivery system, making that DOX-loaded HEP nanogels have significantly superior in vivo antitumor activity.
subject
0Heparin
1Nanogel
2Doxorubicin
3Antitumor
general
0English
1Elsevier Ltd
210.1016/j.biomaterials.2014.11.005
3ScienceDirect (Elsevier B.V.)
4ScienceDirect Journals (Elsevier)
sourceidsciversesciencedirect_elsevier
recordidsciversesciencedirect_elsevierS0142-9612(14)01161-2
issn
001429612
10142-9612
rsrctypearticle
creationdate2015
addtitleBiomaterials
searchscope
0sciversesciencedirect_elsevier
1elsevier_sciencedirect
scope
0sciversesciencedirect_elsevier
1elsevier_sciencedirect
startdate20150101
enddate20150131
citationpf 260 pt 268 vol 39
lsr30VSR-Enriched:[eissn, pqid]
sort
titleBioreducible heparin-based nanogel drug delivery system
authorWu, Wei ; Yao, Wei ; Wang, Xin ; Xie, Chen ; Zhang, Jialiang ; Jiang, Xiqun
creationdate20150100
lso0120150100
facets
frbrgroupid7992482806145935916
frbrtype5
languageeng
creationdate2015
topic
0Heparin
1Nanogel
2Doxorubicin
3Antitumor
collectionScienceDirect Journals (Elsevier)
prefilterarticles
rsrctypearticles
creatorcontrib
0Wu, Wei
1Yao, Wei
2Wang, Xin
3Xie, Chen
4Zhang, Jialiang
5Jiang, Xiqun
jtitleBiomaterials
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
aulast
0Wu
1Yao
2Wang
3Xie
4Zhang
5Jiang
aufirstWei
au
0Wu, Wei
1Yao, Wei
2Wang, Xin
3Xie, Chen
4Zhang, Jialiang
5Jiang, Xiqun
atitleBioreducible heparin-based nanogel drug delivery system
jtitleBiomaterials
risdate201501
volume39
spage260
epage268
pages260-268
issn0142-9612
formatjournal
genrearticle
ristypeJOUR
abstractBioreducible heparin (HEP)-based nanogels were prepared by derivatizing HEP with vinyl group followed by copolymerizing with cystamine bisacrylamide in aqueous medium in the absence of surfactant. The hydrodynamic diameter of the HEP nanogels could be tuned in the range from 80 to 200 nm. Doxorubicin (DOX) was loaded into the HEP nanogels, and high drug loading content (30%) and efficiency (90%) were achieved. In vitro drug release test revealed that this drug delivery system exhibited strongly redox-sensitive drug release behavior that would greatly favor the in vivo drug delivery performance of the nanogels. After injected into tumor-bearing mice through tail vein, the DOX-loaded HEP nanogels showed remarkable accumulation in tumors as demonstrated by in vivo near infared fluorescence imaging and ex vivo DOX concentration measurements. The doxorubicin accumulation at tumor site goes beyond 9% injected dose per gram of tumor through such delivery system, making that DOX-loaded HEP nanogels have significantly superior in vivo antitumor activity.
pubElsevier Ltd
doi10.1016/j.biomaterials.2014.11.005
eissn18785905
date2015-01